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 I
摘要 
人呼吸道合胞病毒（Human Respiratory SyncytiaVirus, hRSV）是全球范围内
引起下呼吸道感染主要病原体之一。其感染人群年龄分布广，新生儿与老年人是
主要高危人群。据报道，几乎所有小于 2 周岁婴幼儿都有 RSV 感染经历，婴幼
儿发病住院率高达 2.5-4%。RSV 引起大于 65 周岁的老年人感染率为 3-4%，病
死率约为 2%。早产儿、先天性心脏病、先天性支气管及肺发育不良、免疫缺陷
的婴幼儿 RSV 病死率率高达 5%，造成严重的医疗负担。 
RSV 无安全、有效疫苗上市，唯一获准上市的预防性 RSV 药物为中和性单
抗 palivizumab (Synagis®)，特异性识别 RSV 融合蛋白。Synagis 在动物体内预防
性试验的成功提示 RSV 感染动物模型的建立有助于疫苗、抗体药物的保护性研
究。RSV 感染动物模型种类繁多，如小鼠、棉鼠、雪貂、猩猩等，每种动物都
有其感染特征。其中，小鼠模型由于易获得近交系及研究用检测试剂等，最常用
于 RSV 感染研究，又以 BALB/c 小鼠应用最广；裸鼠适应性免疫系统缺陷，感
染后鼻、肺内病毒清除延迟，因此可研究先天免疫介导 RSV 引起的气道炎症应
答，模拟免疫缺陷人群 RSV 感染。 
本研究建立不同周龄 BALB/c 小鼠及裸鼠模型，模拟不同易感人群 RSV 感
染后症状，运用该模型对 RSV 特异性抗体进行体内预防性评估，为 RSV 药物的
开发奠定基础。首先，本论文分别选取 10 周龄、30 周龄、60 周龄 BALB/c 小鼠，
分别感染 100 μL 的 107 PFU/mL、108 PFU/mL 滴度的 RSV 后比较其临床症状及
病理变化。结果显示，感染 108 PFU/mL 滴度的 RSV 感染后不同周龄小鼠都有明
显的体重下降；鼻、肺检测到较高滴度病毒；免疫组织化学检测抗原定位于肺泡、
支气管周围的炎症细胞胞浆；引起明显的炎症细胞浸润、肺组织病理损伤；随着
小鼠周龄的增大，RSV 感染后引起的临床症状及病理变化越严重。进一步感染
10 周龄裸鼠，旨在模拟免疫缺陷 RSV 感染症状，结果发现与 BALB/c 小鼠相比，
RSV 并不能使裸鼠体重下降，但裸鼠鼻、肺内病毒滴度高、持续时间久；而裸
鼠肺炎症反应出现较 BALB/c 早，感染后第 3 天即出现明显的炎症反应，第 7 天
后炎症逐渐减轻、恢复；抗原定位在肺泡、支气管周围，以第 3 天最为明显，第
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12 天鲜见有阳性铁锈色反应。说明适应性免疫缺陷裸鼠可利用天然免疫独立介
导 RSV 感染引起的小鼠气道炎症。利用上述已建立好的不同周龄 BALB/c 小鼠
模型，以 1129（Synagis 的鼠源性抗体）作为对照抗体，对实验室筛选的一株特
异性针对 RSV-F 蛋白的强中和抗体 5C4 进行小鼠体内预防性评估，结果显示，
5C4 与 1129 都能有效减轻 RSV 引起的体重下降；降低鼻、肺内病毒滴度；及肺
部炎症反应炎症。而 5C4 在低剂量与 1129 高剂量条件下对小鼠预防性效果一致；
上述现象在不同周龄鼠呈现一致，说明 5C4 抗体在不同周龄 BALB/c 小鼠上都有
良好的预防性效果，其有效剂量为 1129 抗体的 1/10，因此可作为 RSV 预防性药
物潜在开发对象。 
综上所述本论文建立不同周龄 BALB/c 小鼠、裸鼠感染动物模型，模拟不同
人群 RSV 感染临床症状及病理变化，为不同人群 RSV 感染免疫机制的深入研究
及不同年龄段相关抗体和疫苗药物的选择、评估提供依据；同时将 RSV 感染的
BALB/c 模型应用于 RSV 潜力预防性抗体的评估，为新一代 RSV 预防性药物的
开发提供有效的临床前评估平台。 
关键词：呼吸道合胞病毒；动物模型；肺炎支气管炎；中和抗体预防性评估
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Abstract 
Respiratory syncytial virus (RSV) is one of major pathogens for lower 
respiratory tract infection. It has a large infected age distribution, including almost all 
the population from the newborn to the elderly. It is reported that almost all children 
under two-year old have been infected by RSV. Hospitalization of infants due to RSV 
infections is 2.5-4% each year. Data from a variety of studies suggests that adults over 
65 years of age, the overall annual incidence of RSV illness is 3 to 4%, with an 
estimated a fatality rate of 5%. Also, RSV has a reported fatality rate of 5% among 
premature births, congenital bronchial, pulmonary dysplasia and immune deficiency 
individuals, causing a significant medical burden.     
Yet, there is no effective RSV vaccines on the market, the only approved 
anti-RSV drug is a neutralizing antibody palivizumab (Palivizumab) which recognizes 
the RSV fusion protein. Success of palivizumab supported that the building of RSV 
animal model would be helpful for the protection trails of RSV vaccine and antibody 
drugs.  
There is a various type of RSV animal model, such as mice, cotton rats, ferrets, 
chimpanzees and so on, each model has its own charateristics. Among them, mice 
model was used in study of RSV infection most commonly due to easy access to 
inbred and detection reagent and BALB/c mice were most widely used. As lacked the 
adaptive immunity and delayed pulmonary viral clearance, nude mice were always 
used as model to research the innate immunity reponse after RSV infection and 
stimulate the immunocompromised population.  
Our study aimed to build different week-old BALB/c mice model and nude mice 
model of RSV infection, to simulate infection symptoms of different population and 
used these models to evaluate the prophylactic potential of RSV antibodies. First, 
young (10 weeks), middle aged (30 weeks) and aged (60 weeks) mice were 
intranasally infected with 106 plaque-forming units (PFU) or 107 PFU RSVA2 strains, 
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lung virus titer, histology and immunohistochemistry was examined, and age 
sensitivity was analyzed. A high-titer virus infection showed an obvious symptom. 
Mice trended to be more susceptible to RSV infection as the growth of age. Titers up 
to 106.5 PFU/gram lung can be attained in 60-week-old mice. Older mice experience 
more weight loss. Lung histology of older mice showed more serious bronchiolitis 
and increased number of inflammatory cells in alveolar spaced compared with that of 
younger mice. Further, 10 weeks BALB/c mice and nude mice were intranasally 
infected with 107 PFU RSVA2 strains, simulating infection symptom of immune 
deficiency population. Comparing with BALB/c mice, nude mice showed no weight 
loss, while 106.5 PFU/gram virus titer was attained in nude mice at day3 and 
104.3PFU/gram maintained at day20. Nude mice showed early bronchiolitis compared 
with that of BALB/c mice. RSV antigen located around the alveolar and broncho and 
detected less at day12.  
Using these animal model, we aimed to evaluate prophylaxitic potential of pre-F 
specific antibody 5C4. It was obersvered that compared with 1129, antibody 5C4 
exhibited significant advantage in the terms of prophylactic efficacy, in ech week-old 
group, suggesting that it is potential to be commercialized and replaces the previous 
product palivizumab. It showed that 5C4 and 1129 can effectively reduce weight loss, 
lung and nose virus titer and lung pathology induced by RSV. And 5C4 in the low 
dose had the similar effect with high dose of 1129. The above phenomenon could 
show in different ages, indicating that antibody 5C4 have a good preventive effect in 
different week old BALB / c mice and the effective dose is one tenth of 1129 antibody. 
Therefore, it can be used as RSV potential prophylaxis. 
In this study, we successfully established a different week-old BALB/c mice 
model and nude mice model, simulating the pathology and symptom of different 
populations after RSV infection and providing a basis for the further study of the 
immune mechanism in different populations and the selection and evaluation of 
different age related vaccines. Also, using these animal model, we can evaluate the 
prophylaxitic potential of highly efficient neutralizing antibody which will serve as 
the platform for development of new RSV potential antibody. 
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Key words: RSV; animal model; pneumonia and bronchitis; prophylaxitic potential 
evaluation 
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缩略词 
英文缩写 英文全称 中文全称 
hRSV human respiratory syncytial virus 人类呼吸道合胞病毒 
RSV A2 respiratory syncytial virus strain A2 呼吸道合胞病毒 A2 株 
RSV-A subgroup A of respiratory syncytial virus A 亚型呼吸道合胞病毒 
RSV-B subgroup B of respiratory syncytial virus B 亚型呼吸道合胞病毒 
FI-RSV formalin inactivated RSV vaccine 福尔马林灭活 RSV 疫苗 
DNA deoxyribonucleic acid 脱氧核苷酸 
RNA ribonucleic acid 核糖核酸 
mRNA messenger ribonucleic acid 信使核糖核酸 
G protein glycoprotein 糖蛋白 
F protein fusion protein 融合蛋白 
M protein matrix protein 基质蛋白 
P protein phosphoprotein 磷蛋白 
SH protein small hydrophobic protein 小疏水蛋白 
L protein large nucleoprotein 大核蛋白 
N protein nucleoprotein 核蛋白 
EM electron microscopy 电子显微镜 
kb kilo base pair 千碱基对 
bp base pair 碱基对 
KD kilo nucleotide 千道尔顿 
ddH2O ddH2O 双蒸水 
PFU plaque forming units 嗜空斑形成单位 
IgG Immunoglobulin G 免疫球蛋白 G 
mAb monoclonal antibody 单克隆抗体 
Kan Kanamycin 卡那霉素 
Amp Ampicillin 氨苄西林 
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PBS phosphate buffered saline 磷酸盐溶液 
FBS fetal bovine serum 胎牛血清 
FDA Food and drug Administration  食品药物管理局 
HE hematoxylin-eosin staining 苏木精-伊红染色 
IHC immunohistochemistry 免疫组织化学反应 
IFN-γ γ-interferon γ-干扰素 
NPA Nasopharyngeal aspirate 鼻咽抽吸物 
rpm Revolutions per minute 每分钟转速 
DMSO Dimethylsulfoxide 二甲基亚砜 
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